Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by snuff133on Feb 23, 2021 9:11am
97 Views
Post# 32635089

RE:RE:RE:News!

RE:RE:RE:News!Dear Friend;

Attached is a news release announcing a stud of heart valve disease in children.  Here is some background:

1.      When the valve between the atrium and ventricle is defective it leads to back flow due to incomplete closure (also known as regurgitation).  This means the atrium has to work harder to push blood into the ventricle and the ventricle has to work harder to pump blood away from the heart.
2.      This true for both the right and left side and can cause heart failure on either side.
4.      The VMS+3.0 is uniquely able to accurately and reliably measure size (volume) and ejection fraction for all 4 chambers of the heart and so for the first time, cardiologists can easily measure the function of the atria and ventricles using 2D ultrasound. There is no more need for the hit snd miss use of 3D echo or an arduous MRI procedure, which is not done frequently enough to adequately monitor the heart.
5.      The purpose of the study is to allow for sequential frequent assessments of children’s hearts as they grow and the heart also gets bigger.  The need here is to see if any of the chambers of the heart is enlarging disproportionately as this is the first sign of valvular disease.
6.      It is vitally important the stress on the heart is detected early and the valve corrected before the heart becomes permanently enlarged and damaged.  Hence it is important to have frequent 2D echocardiograms and the VMS+3.0 is a gentler way to repeatedly evaluate these children. 

Thank you for your continued support and interest as Ventripoint continues its mission to improve heart diagnostics and care for all worldwide and especially for children.

Regards,
<< Previous
Bullboard Posts
Next >>